Condition: Ischemic Cardiomyopathy · Catheter Ablation of Ventricular Tachycardia · Sponsor: Rennes University Hospital
Radiofrequency ablation of ventricular tachycardias (VTs) is the gold standard treatment of refractory VTs in patients with ischaemic heart disease. In this setting, ablation is usually performed endocardially. However, even after a procedural success there is a high risk of recurrence, particularly due to the inability to create transmural lesions. Indeed, only the endocardium of the LV has been ablated, while a significant part of the arrhythmia substrate may be located on the other side of the myocardial thickness, on the epicardial side of the LV. First described in 1996, epicardial ablation, performed via a percutaneous subxyphoid approach, has since undergone considerable development. Electrophysiologists often use a double endo- and epicardial approach as first line therapy for the ablation of VTs complicating myocarditis or arrhythmogenic dysplasia of the right ventricle, where the substrate is most often epicardial. For VT in ischaemic heart disease, electrophysiologists perform endocardial ablation, and often perform epicardial ablation only after several endocardial failures. Several observational studies suggest that a combined endo- and epicardial approach as first line therapy is associated with a reduced risk of VT recurrence. Since recurrent VT in patients with ischaemic heart disease as a prognostic impact in terms of morbidity and mortality, it appears essential to optimise rhythm management by ablation, by offering a combined approach from the as first ap…
This description comes directly from the study's public registry record.
Raphaël MARTINS, MD, PhD · 299282517 · raphael.martins@chu-rennes.fr
Kristell COAT · 299282555 · kristell.coat@chu-rennes.fr
Always discuss trial participation with your own doctor first.
| CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Caen | Caen, France | Not Yet Recruiting |
| Centre Hospitalier de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| Centre Hospitalier Régional Universitaire de Lille | Lille, France | Not Yet Recruiting |
| Hospices Civils de Lyon | Lyon, France | Not Yet Recruiting |
| CHU de Nantes | Nantes, France | Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Recruiting |
| Hôpital Universitaire La Pitié-Salpêtrière - Paris | Paris, France | Not Yet Recruiting |
| CHU de Rennes | Rennes, France | Recruiting |
| Centre Hospitalier Universitaire de Saint-Étienne | Saint-Etienne, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire Toulouse - Hôtel Dieu Saint-Jacques | Toulouse, France | Not Yet Recruiting |
| Centre Hospitalier Régional Universitaire Tours - Hôpital Bretonneau | Tours, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05888662